176 related articles for article (PubMed ID: 9235086)
1. [Multidrug resistance (MDR) in oncology].
Souvirón Rodríguez A; Ruiz Gómez MJ; Morales Moreno JA; Martínez Morillo M
An Med Interna; 1997 Mar; 14(3):145-53. PubMed ID: 9235086
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
3. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
5. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressors and reversion of multidrug-resistance.
Aouali N; Eddabra L; Macadré J; Morjani H
Crit Rev Oncol Hematol; 2005 Oct; 56(1):61-70. PubMed ID: 15978826
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
11. New multidrug-resistance-reversing drugs, MS-209 and SDZ PSC 833.
Naito M; Tsuruo T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S20-4. PubMed ID: 9272129
[TBL] [Abstract][Full Text] [Related]
12. The role of passive transbilayer drug movement in multidrug resistance and its modulation.
Eytan GD; Regev R; Oren G; Assaraf YG
J Biol Chem; 1996 May; 271(22):12897-902. PubMed ID: 8662680
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1]-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein.
Archinal-Mattheis A; Rzepka RW; Watanabe T; Kokubu N; Itoh Y; Combates NJ; Bair KW; Cohen D
Oncol Res; 1995; 7(12):603-10. PubMed ID: 8704277
[TBL] [Abstract][Full Text] [Related]
14. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance inhibition by antisense oligonucleotide against MDR1/mRNA in P-glycoprotein expressing leukemic cells.
Nadali F; Pourfathollah AA; Alimoghaddam K; Nikougoftar M; Rostami S; Dizaji A; Azizi E; Zomorodipour A; Ghavamzadeh A
Hematology; 2007 Oct; 12(5):393-401. PubMed ID: 17852455
[TBL] [Abstract][Full Text] [Related]
16. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.
Le Bot MA; Kernaleguen D; Robert J; Berlion M; Riché C
Cancer Chemother Pharmacol; 1994; 35(1):53-8. PubMed ID: 7987977
[TBL] [Abstract][Full Text] [Related]
17. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
[TBL] [Abstract][Full Text] [Related]
19. Differences in sensitivity to UVC, UVB and UVA radiation of a multidrug-resistant cell line overexpressing P-glycoprotein.
Trindade GS; Capella MA; Capella LS; Affonso-Mitidieri OR; Rumjanek VM
Photochem Photobiol; 1999 Jun; 69(6):694-9. PubMed ID: 10378008
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance: lessons from clinical oncology.
Bates SF; Chen C; Robey R; Kang M; Figg WD; Fojo T
Novartis Found Symp; 2002; 243():83-96; discussion 96-102, 180-5. PubMed ID: 11990784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
